Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.

Papadopoulos KP, Johnson ML, Lockhart AC, Moore KN, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner R, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR.

Clin Cancer Res. 2019 Dec 3. pii: clincanres.2609.2019. doi: 10.1158/1078-0432.CCR-19-2609. [Epub ahead of print]

PMID:
31796520
2.

The "Radical" Palliation That Increases Survival in Malignant Pleural Mesothelioma.

Fodor A, Picchio M, Incerti E, Formenti SC, Di Muzio NG.

J Thorac Oncol. 2019 Dec;14(12):e282-e283. doi: 10.1016/j.jtho.2019.07.030. No abstract available.

PMID:
31757384
3.

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial.

Demaria S, Romano E, Brackstone M, Formenti SC.

J Immunother Cancer. 2019 Nov 21;7(1):318. doi: 10.1186/s40425-019-0783-x.

4.

Worldwide Access to Stereotactic Radiosurgery.

Pannullo SC, Julie DAR, Chidambaram S, Balogun OD, Formenti SC, Apuzzo MLJ, Knisely JPS.

World Neurosurg. 2019 Oct;130:608-614. doi: 10.1016/j.wneu.2019.04.031.

PMID:
31581410
5.

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.

Formenti SC, Hawtin RE, Dixit N, Evensen E, Lee P, Goldberg JD, Li X, Vanpouille-Box C, Schaue D, McBride WH, Demaria S.

J Immunother Cancer. 2019 Jul 11;7(1):177. doi: 10.1186/s40425-019-0633-x.

6.

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy-A Radiobiological Sin.

Ko EC, Vanpouille-Box C, Formenti SC.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1882. [Epub ahead of print] No abstract available.

PMID:
31268473
7.

Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system.

Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S.

Genome Med. 2019 Jun 20;11(1):40. doi: 10.1186/s13073-019-0653-7.

8.

Enhancing Career Paths for Tomorrow's Radiation Oncologists.

Vapiwala N, Thomas CR Jr, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD Jr, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN.

Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):52-63. doi: 10.1016/j.ijrobp.2019.05.025. Epub 2019 May 22. Review. No abstract available.

PMID:
31128144
9.

Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality.

Ko EC, Formenti SC.

Int J Radiat Biol. 2019 Jul;95(7):936-939. doi: 10.1080/09553002.2019.1623429. Epub 2019 Jun 13. Review.

PMID:
31120369
10.

Shaping the Path for a Global Oncology Academic Career.

Balogun OD, Choi AMK, Formenti SC.

JAMA Oncol. 2019 Jul 1;5(7):931-932. doi: 10.1001/jamaoncol.2019.0555. No abstract available.

PMID:
31046103
11.

Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.

Marciscano AE, Haimovitz-Friedman A, Lee P, Tran PT, Tomé WA, Guha C, Spring Kong FM, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, DeWeese TL.

Int J Radiat Oncol Biol Phys. 2019 Mar 2. pii: S0360-3016(19)30290-1. doi: 10.1016/j.ijrobp.2019.02.046. [Epub ahead of print] No abstract available.

PMID:
30836168
12.

Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century.

Beeler WH, Griffith KA, Jones RD, Chapman CH, Holliday EB, Lalani N, Wilson E, Bonner JA, Formenti SC, Hahn SM, Kalnicki S, Liu FF, Movsas B, Thomas CR Jr, Jagsi R.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):979-986. doi: 10.1016/j.ijrobp.2019.01.074. Epub 2019 Jan 23.

PMID:
30684662
13.

Radiotherapy induces responses of lung cancer to CTLA-4 blockade.

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S.

Nat Med. 2018 Dec;24(12):1845-1851. doi: 10.1038/s41591-018-0232-2. Epub 2018 Nov 5.

14.

Estimating child mortality associated with maternal mortality from breast and cervical cancer.

Mailhot Vega RB, Balogun OD, Ishaq OF, Bray F, Ginsburg O, Formenti SC.

Cancer. 2019 Jan 1;125(1):109-117. doi: 10.1002/cncr.31780. Epub 2018 Nov 1.

PMID:
30383913
15.

Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation.

Ko EC, Benjamin KT, Formenti SC.

Adv Radiat Oncol. 2018 Oct 23;3(4):486-493. doi: 10.1016/j.adro.2018.08.021. eCollection 2018 Oct-Dec. Review.

16.

Introduction to the special edition on immunotherapy and radiation oncology.

Bornstein S, Formenti SC.

Adv Radiat Oncol. 2018 Oct 23;3(4):484-485. doi: 10.1016/j.adro.2018.08.019. eCollection 2018 Oct-Dec. No abstract available.

17.

Cytosolic DNA Sensing in Organismal Tumor Control.

Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L.

Cancer Cell. 2018 Sep 10;34(3):361-378. doi: 10.1016/j.ccell.2018.05.013. Epub 2018 Jun 28. Review.

18.

Percutaneous Cryoablation for the Management of Chronic Pain Secondary to Locally Recurrent Rectal Cancer with Bowel and Nerve Root Involvement.

Cornman-Homonoff J, Formenti SC, Chachoua A, Madoff DC.

J Vasc Interv Radiol. 2018 Sep;29(9):1296-1298. doi: 10.1016/j.jvir.2018.02.022. No abstract available.

PMID:
30146202
19.

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect.

Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S.

Trends Immunol. 2018 Aug;39(8):644-655. doi: 10.1016/j.it.2018.06.001. Epub 2018 Jul 11. Review.

20.

The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.

Ko EC, Raben D, Formenti SC.

Clin Cancer Res. 2018 Dec 1;24(23):5792-5806. doi: 10.1158/1078-0432.CCR-17-3620. Epub 2018 Jun 26. Review.

21.

Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway.

Durante M, Formenti SC.

Front Oncol. 2018 May 29;8:192. doi: 10.3389/fonc.2018.00192. eCollection 2018. Review.

22.

Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.

Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, Pilones KA, Sarfraz Y, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Aug;6(8):910-920. doi: 10.1158/2326-6066.CIR-17-0581. Epub 2018 Jun 15.

23.

Understanding Responses to Stereotactic Body Radiotherapy and Pembrolizumab.

Formenti SC, Demaria S.

J Clin Oncol. 2018 Sep 1;36(25):2661-2662. doi: 10.1200/JCO.2018.78.7622. Epub 2018 Jun 5. No abstract available.

PMID:
29870291
24.

Hypofractionated Whole-Breast Irradiation in Women Less Than 50 Years Old Treated on 4 Prospective Protocols.

Shaikh F, Chew J, Hochman T, Purswani J, Maisonet O, Peat E, Huppert N, Cooper BT, Tam M, Goldberg JD, Perez CA, Formenti SC, Gerber NK.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1159-1167. doi: 10.1016/j.ijrobp.2018.04.034. Epub 2018 Apr 19.

PMID:
29859789
25.

Radiotherapy and checkpoint inhibitors: a winning new combination?

Ko EC, Formenti SC.

Ther Adv Med Oncol. 2018 Apr 11;10:1758835918768240. doi: 10.1177/1758835918768240. eCollection 2018. Review.

26.

Dual Transforming Growth Factor-β and Programmed Death-1 Blockade: A Strategy for Immune-Excluded Tumors?

Vanpouille-Box C, Formenti SC.

Trends Immunol. 2018 Jun;39(6):435-437. doi: 10.1016/j.it.2018.03.002. Epub 2018 Mar 26.

28.

PTEN at the interface of immune tolerance and tumor suppression.

Brandmaier A, Hou SQ, Demaria S, Formenti SC, Shen WH.

Front Biol (Beijing). 2017 Jun;12(3):163-174. doi: 10.1007/s11515-017-1443-5. Epub 2017 Mar 4.

29.
30.

Qualitative Assessment of Academic Radiation Oncology Department Chairs' Insights on Diversity, Equity, and Inclusion: Progress, Challenges, and Future Aspirations.

Jones RD, Chapman CH, Holliday EB, Lalani N, Wilson E, Bonner JA, Movsas B, Kalnicki S, Formenti SC, Thomas CR Jr, Hahn SM, Liu FF, Jagsi R; Society of Chairs of Academic Radiation Oncology Programs (SCAROP).

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):30-45. doi: 10.1016/j.ijrobp.2018.01.012. Epub 2018 Jan 9.

PMID:
29477292
31.

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer.

Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH.

Clin Cancer Res. 2018 Jun 1;24(11):2493-2504. doi: 10.1158/1078-0432.CCR-17-3322. Epub 2018 Feb 23.

32.

Using immunotherapy to boost the abscopal effect.

Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC.

Nat Rev Cancer. 2018 May;18(5):313-322. doi: 10.1038/nrc.2018.6. Epub 2018 Feb 16. Review.

33.

Optimizing Dose Per Fraction: A New Chapter in the Story of the Abscopal Effect?

Formenti SC.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):677-679. doi: 10.1016/j.ijrobp.2017.07.028. No abstract available.

PMID:
29280462
34.

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S.

Semin Cancer Biol. 2018 Oct;52(Pt 2):125-134. doi: 10.1016/j.semcancer.2017.12.007. Epub 2017 Dec 16. Review.

35.

Integration of radiation and immunotherapy in breast cancer - Treatment implications.

Ye JC, Formenti SC.

Breast. 2018 Apr;38:66-74. doi: 10.1016/j.breast.2017.12.005. Epub 2018 Jan 4. Review.

PMID:
29253718
36.

Metastatic Osseous Pain Control: Radiation Therapy.

Kang J, Formenti SC.

Semin Intervent Radiol. 2017 Dec;34(4):322-327. doi: 10.1055/s-0037-1608703. Epub 2017 Dec 14. Review.

37.

Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.

Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S.

Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.

38.

Trial watch: Immune checkpoint blockers for cancer therapy.

Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2017 Aug 31;6(11):e1373237. doi: 10.1080/2162402X.2017.1373237. eCollection 2017. Review.

39.

Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M.

J Transl Med. 2017 Nov 16;15(1):236. doi: 10.1186/s12967-017-1341-2.

40.

TREX1 dictates the immune fate of irradiated cancer cells.

Vanpouille-Box C, Formenti SC, Demaria S.

Oncoimmunology. 2017 Jun 16;6(9):e1339857. doi: 10.1080/2162402X.2017.1339857. eCollection 2017.

41.

Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs.

Holliday EB, Bonner JA, Formenti SC, Hahn SM, Kalnicki S, Liu FF, Movsas B, Fuller CD, Thomas CR Jr.

J Healthc Manag. 2017 Sep/Oct;62(5):302-313. doi: 10.1097/JHM-D-16-00001.

PMID:
28885530
42.

In Regard to Rahimi et al.

Gerber NK, Formenti SC.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):498-499. doi: 10.1016/j.ijrobp.2017.05.047. No abstract available.

PMID:
28872002
43.

Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.

Vanpouille-Box C, Formenti SC, Demaria S.

Clin Cancer Res. 2018 Jan 15;24(2):259-265. doi: 10.1158/1078-0432.CCR-16-0037. Epub 2017 Jul 27. Review.

44.

Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters.

Cooper BT, Li X, Shin SM, Modrek AS, Hsu HC, DeWyngaert JK, Jozsef G, Lymberis SC, Goldberg JD, Formenti SC.

Adv Radiat Oncol. 2016 Aug 9;1(4):373-381. doi: 10.1016/j.adro.2016.08.001. eCollection 2016 Oct-Dec.

45.

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S.

Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618.

46.

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P.

Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Erratum in: Lancet Oncol. 2017 Jul;18(7):e371.

47.

Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.

Formenti SC, Golden EB, Goldberg JD, Li X, Taff J, Fenton-Kerimian MB, Chandrasekhar S, Demaria S, Novik Y.

Oncoimmunology. 2016 Dec 27;6(3):e1274479. doi: 10.1080/2162402X.2016.1274479. eCollection 2017.

48.

Barriers to Radiation-Induced In Situ Tumor Vaccination.

Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC, Demaria S.

Front Immunol. 2017 Mar 13;8:229. doi: 10.3389/fimmu.2017.00229. eCollection 2017. Review.

49.

Does Heavy Ion Therapy Work Through the Immune System?

Durante M, Brenner DJ, Formenti SC.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):934-936. doi: 10.1016/j.ijrobp.2016.08.037. Epub 2016 Sep 5. No abstract available.

PMID:
27869095
50.

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.

Galluzzi L, Bravo-San Pedro JM, Demaria S, Formenti SC, Kroemer G.

Nat Rev Clin Oncol. 2017 Apr;14(4):247-258. doi: 10.1038/nrclinonc.2016.183. Epub 2016 Nov 15. Review.

PMID:
27845767

Supplemental Content

Loading ...
Support Center